In GC, although multiple studies have linked PHOX1 overexpression to advanced tumor stages and poor prognosis [13–15], its precise regulatory mechanisms and downstream effectors remain poorly characterized, particularly with respect to epigenetic control and GC-specific signaling networks. Here, PRRX1 is linked to neoplasm.